1. Pink Sheet
  2. >>Geography
  3. >>Europe

Pfizer Ponders Next Move After English HTA Rejects Oxbryta Again Despite Appeal

 
• By Francesca Bruce

In spite of successfully appealing against previous negative guidance, Pfizer has again failed to secure a positive recommendation from England’s health technology appraisal institute for Oxbryta for hemolytic anemia caused by sickle cell disease, and has been asked to provide more evidence.

Red pen marks checkbox with a cross.
England's NICE still wants more data for Pfizer's Oxbryta • Source: Shutterstock

NICE, the health technology appraisal (HTA) institute for England and Wales, has again recommended against making Pfizer Inc.’s sickle cell disease (SCD) drug Oxbryta (voxelotor) available via the National Health Service. The institute is asking Pfizer for more data that might help reduce its outstanding uncertainties.

NICE’s decision, published in the form of new draft guidance, follows Pfizer’s successful appeal against previous final draft guidance from NICE that rejected the drug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

Commission Taking ‘Due Account’ Of Scathing Report On EU Clinical Trial Bottlenecks

 
• By Vibha Sharma

A report by the European pharmaceutical industry criticizes the EU’s clinical trials framework, highlighting regulatory fragmentation, inefficiencies and the need for targeted reforms.

EU Moment Of Truth For Obe-Cel And 10 Other New Medicines

 
• By Neena Brizmohun

Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU.

More from Geography

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

Commission Taking ‘Due Account’ Of Scathing Report On EU Clinical Trial Bottlenecks

 
• By Vibha Sharma

A report by the European pharmaceutical industry criticizes the EU’s clinical trials framework, highlighting regulatory fragmentation, inefficiencies and the need for targeted reforms.